

Marie Lordkipanidze

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1157803/publications.pdf>

Version: 2024-02-01

107
papers

3,024
citations

218381

26
h-index

182168

51
g-index

110
all docs

110
docs citations

110
times ranked

3544
citing authors

#	ARTICLE	IF	CITATIONS
1	Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison. <i>Platelets</i> , 2022, 33, 298-303.	1.1	3
2	Rare missense variants in Tropomyosin-4 (TPM4) are associated with platelet dysfunction, cytoskeletal defects, and excessive bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 478-485.	1.9	3
3	Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 805525.	1.1	12
4	Editorial: Established and Novel Roles of Platelets in Health and Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 835615.	1.1	2
5	A randomized double-blind feasibility study comparing cetirizine and diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions: the PREMEDI-F1 study. <i>Supportive Care in Cancer</i> , 2022, 30, 3389-3399.	1.0	3
6	Clinical Correlates Identify ProBDNF and Thrombo-Inflammatory Markers as Key Predictors of Circulating p75NTR Extracellular Domain Levels in Older Adults. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 821865.	1.7	1
7	Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1443-1453.	1.8	3
8	Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study—a cross-sectional study. <i>BMJ Open</i> , 2022, 12, e055454.	0.8	1
9	Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines. <i>Frontiers in Pharmacology</i> , 2022, 13, 878416.	1.6	2
10	Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2127-2135.	1.9	6
11	Differential correlation of serum BDNF and microRNA content in rats with rapid or late onset of heavy alcohol use. <i>Addiction Biology</i> , 2021, 26, e12890.	1.4	17
12	Acetylcholinesterase inhibitors and risk of bleeding and acute ischemic events in non-hypertensive Alzheimer's patients. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12184.	1.8	2
13	Tissue-Specificity of Antibodies Raised Against TrkB and p75NTR Receptors; Implications for Platelets as Models of Neurodegenerative Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 606861.	2.2	6
14	Platelet Quiescence in Patients With Acute Coronary Syndrome Undergoing Coronary Artery Bypass Graft Surgery. <i>Journal of the American Heart Association</i> , 2021, 10, e016602.	1.6	2
15	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1364-1371.	1.9	19
16	Platelet Function in Viral Immunity and SARS-CoV-2 Infection. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 419-426.	1.5	14
17	A randomized double-blind pilot study comparing cetirizine with diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions. <i>Journal of Clinical Oncology</i> , 2021, 39, e24080-e24080.	0.8	0
18	Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel. <i>Cell Reports Medicine</i> , 2021, 2, 100299.	3.3	2

#	ARTICLE	IF	CITATIONS
19	Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada. <i>CJC Open</i> , 2021, 3, 814-821.	0.7	3
20	The effect of aging on the bone healing properties of blood plasma. <i>Injury</i> , 2021, 52, 1697-1708.	0.7	4
21	A Meta-Analysis of the Effect of Paper Versus Digital Reading on Reading Comprehension in Health Professional Education. <i>American Journal of Pharmaceutical Education</i> , 2021, 85, 8525.	0.7	2
22	Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3193-3202.	1.9	20
23	Brain-Derived Neurotrophic Factor Mitigates the Association Between Platelet Dysfunction and Cognitive Impairment. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 739045.	1.1	9
24	Differences in platelet-rich plasma composition influence bone healing. <i>Journal of Clinical Periodontology</i> , 2021, 48, 1613-1623.	2.3	11
25	The brain-derived neurotrophic factor prompts platelet aggregation and secretion. <i>Blood Advances</i> , 2021, 5, 3568-3580.	2.5	14
26	Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13079.	1.8	20
27	A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1298-1307.	0.8	12
28	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 732-739.	1.9	64
29	Platelet count and disease – editorial policy. <i>Platelets</i> , 2020, 31, 969-970.	1.1	5
30	Postoperative Administration of the Acetylcholinesterase Inhibitor, Donepezil, Interferes with Bone Healing and Implant Osseointegration in a Rat Model. <i>Biomolecules</i> , 2020, 10, 1318.	1.8	8
31	Advances in Platelet Function Testing – Light Transmission Aggregometry and Beyond. <i>Journal of Clinical Medicine</i> , 2020, 9, 2636.	1.0	31
32	Platelets Selectively Regulate the Release of BDNF, But Not That of Its Precursor Protein, proBDNF. <i>Frontiers in Immunology</i> , 2020, 11, 575607.	2.2	31
33	Head-to-Head Comparison of Consensus-Recommended Platelet Function Tests to Assess P2Y12 Inhibition – Insights for Multi-Center Trials. <i>Journal of Clinical Medicine</i> , 2020, 9, 332.	1.0	2
34	Severity of Megakaryocyte-Driven Osteosclerosis in <i>Mpig6b</i> -Deficient Mice Is Sex-Linked. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 803-813.	3.1	9
35	Effects of reading media on reading comprehension in health professional education: a systematic review protocol. <i>JB Evidence Synthesis</i> , 2020, 18, 2633-2639.	0.6	1
36	ASSOCIATION OF PLATELET ACTIVITY WITH CIRCULATING LEVELS OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) AND COGNITIVE FUNCTION: A CROSS-SECTIONAL STUDY. <i>Canadian Journal of Cardiology</i> , 2019, 35, S122.	0.8	0

#	ARTICLE	IF	CITATIONS
37	EFFECT OF LOSARTAN ON PLATELET RESPONSES TO CLASSIC AGONISTS. Canadian Journal of Cardiology, 2019, 35, S26.	0.8	0
38	LARGE-SCALE ASSESSMENT OF PLATELET DIFFERENTIAL SECRETION. Canadian Journal of Cardiology, 2019, 35, S127-S128.	0.8	0
39	Platelet Function in Aging. Frontiers in Cardiovascular Medicine, 2019, 6, 109.	1.1	61
40	Clinical Tests of Platelet Function. , 2019, , 593-608.		1
41	750. Critical Care Medicine, 2019, 47, 354.	0.4	0
42	Study of the bioaccumulation of tinzaparin in renally impaired patients when given at prophylactic doses - The STRIP study. Thrombosis Research, 2019, 174, 48-50.	0.8	4
43	Increased platelet reactivity and platelet leukocyte aggregation after elective coronary bypass surgery. Platelets, 2019, 30, 975-981.	1.1	12
44	Clinical importance of thrombocytopenia in patients with acute coronary syndromes: a systematic review and meta-analysis. Platelets, 2019, 30, 817-827.	1.1	1
45	Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y ₁₂ receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 543-553.	0.4	15
46	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Canadian Journal of Cardiology, 2018, 34, 214-233.	0.8	181
47	Platelets at the heart of therapy. Platelets, 2018, 29, 103-104.	1.1	0
48	Personalizing antiplatelet therapies: What have we learned from recent trials?. Platelets, 2018, 29, 131-139.	1.1	8
49	An interview with Professor Gus Born. Platelets, 2018, 29, 744-748.	1.1	1
50	Impact of preoperative use of P2Y ₁₂ receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 753-770.	0.4	53
51	Mice Lacking the Inhibitory Collagen Receptor LAIR-1 Exhibit a Mild Thrombocytosis and Hyperactive Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 823-835.	1.1	28
52	Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid. Thrombosis Research, 2017, 149, 64-69.	0.8	12
53	Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial. Journal of Thoracic Disease, 2017, 9, E440-E443.	0.6	2
54	Platelet Function Tests. , 2017, , 559-570.		2

#	ARTICLE	IF	CITATIONS
55	Vorapaxar and diplopia: Possible off-target PAR-receptor modulation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 905-910.	1.8	5
56	Platelet Function Tests. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 258-267.	1.5	57
57	Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects. <i>Haematologica</i> , 2016, 101, 1170-1179.	1.7	119
58	ISCHEMIC AND BLEEDING OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING AMONG PATIENTS INITIALLY TREATED WITH A P2Y12 RECEPTOR ANTAGONIST FOR ACUTE CORONARY SYNDROMES - INSIGHTS ON THE USE OF TICAGRELOR VERSUS CLOPIDOGREL PRIOR TO SURGERY. <i>Canadian Journal of Cardiology</i> , 2016, 32, S118-S119.	0.8	0
59	ISCHEMIC AND BLEEDING OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING AMONG PATIENTS INITIALLY TREATED WITH A P2Y12 RECEPTOR ANTAGONIST FOR ACUTE CORONARY SYNDROMES - INSIGHTS ON TIMING OF DISCONTINUATION OF TICAGRELOR AND CLOPIDOGREL PRIOR TO SURGERY. <i>Canadian Journal of Cardiology</i> , 2016, 32, S252.	0.8	0
60	The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 500-512.	2.3	13
61	Platelet function testing as a biomarker for efficacy of antiplatelet drugs. <i>Biomarkers in Medicine</i> , 2016, 10, 903-918.	0.6	8
62	Is platelet transfusion the solution to reverse platelet inhibition in patients on triple antiplatelet therapy?. <i>Thrombosis Research</i> , 2015, 136, 1057-1058.	0.8	1
63	Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review. <i>Systematic Reviews</i> , 2015, 4, 88.	2.5	7
64	Diversity and impact of rare variants in genes encoding the platelet G protein-coupled receptors. <i>Thrombosis and Haemostasis</i> , 2015, 113, 826-837.	1.8	15
65	Use of next-generation sequencing and candidate gene analysis to identify underlying defects in patients with inherited platelet function disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 643-650.	1.9	63
66	The role of platelets in the recruitment of leukocytes during vascular disease. <i>Platelets</i> , 2015, 26, 507-520.	1.1	146
67	Evidence of platelet sensitization to ADP following discontinuation of clopidogrel therapy in patients with stable coronary artery disease. <i>Platelets</i> , 2015, 26, 545-551.	1.1	7
68	SLFN14 mutations underlie thrombocytopenia with excessive bleeding and platelet secretion defects. <i>Journal of Clinical Investigation</i> , 2015, 125, 3600-3605.	3.9	71
69	The prognostic utility of tests of platelet function for the detection of "aspirin resistance"™ in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-366.	1.3	22
70	A novel thromboxane A2 receptor N42S variant results in reduced surface expression and platelet dysfunction. <i>Thrombosis and Haemostasis</i> , 2014, 112, 923-932.	1.8	19
71	Methodological issues and recommendations for systematic reviews of prognostic studies: an example from cardiovascular disease. <i>Systematic Reviews</i> , 2014, 3, 140.	2.5	19
72	Evaluation of a whole blood remote platelet function test for the diagnosis of mild bleeding disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 660-665.	1.9	40

#	ARTICLE	IF	CITATIONS
73	A novel mutation in the P2Y12 receptor and a functionâ€reducing polymorphism in proteaseâ€activated receptorâ€1 in a patient with chronic bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 716-725.	1.9	40
74	Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay. <i>Blood</i> , 2014, 123, e11-e22.	0.6	60
75	Protocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease. <i>Systematic Reviews</i> , 2013, 2, 16.	2.5	5
76	Genotyping and phenotyping of platelet function disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 351-363.	1.9	62
77	Testing Platelet Function. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 411-441.	0.9	52
78	Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1627-1639.	1.9	28
79	Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects. <i>Blood</i> , 2013, 122, 4090-4093.	0.6	108
80	OC-13 Investigation of underlying platelet function defects in patients with unexplained menorrhagia. <i>Thrombosis Research</i> , 2013, 131, S74.	0.8	1
81	Clinical Tests of Platelet Function. , 2013, , 519-545.		9
82	Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1663-1668.	1.9	103
83	Microsatellite markers as a rapid approach for autozygosity mapping in Hermansky-Pudlak syndrome: Identification of the second HPS7 mutation in a patient presenting late in life. <i>Thrombosis and Haemostasis</i> , 2013, 109, 766-768.	1.8	22
84	Simultaneous measurement of ATP release and LTA does not potentiate platelet aggregation to epinephrine. <i>Thrombosis and Haemostasis</i> , 2013, 110, 199-201.	1.8	6
85	Platelet Turnover in Atherothrombotic Disease. <i>Current Pharmaceutical Design</i> , 2012, 18, 5328-5343.	0.9	20
86	Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel. <i>Blood</i> , 2012, 120, 5041-5049.	0.6	92
87	50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart Adams. <i>Platelets</i> , 2012, 23, 415-422.	1.1	40
88	Advances in monitoring of aspirin therapy. <i>Platelets</i> , 2012, 23, 526-536.	1.1	35
89	Aspirin twice a day keeps new COX-1 at bay. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1217-1219.	1.9	20
90	G6f-Like Is an ITAM-Containing Collagen Receptor in Thrombocytes. <i>PLoS ONE</i> , 2012, 7, e52622.	1.1	9

#	ARTICLE	IF	CITATIONS
91	Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. <i>International Journal of Cardiology</i> , 2011, 150, 39-44.	0.8	31
92	Genetic determinants of response to aspirin: Appraisal of 4 candidate genes. <i>Thrombosis Research</i> , 2011, 128, 47-53.	0.8	32
93	Beware of being caught on the rebound. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 21-23.	1.9	9
94	Why an aspirin a day no longer keeps the doctor away â€¦. <i>Thrombosis and Haemostasis</i> , 2011, 105, 209-210.	1.8	13
95	Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin. <i>International Journal of Cardiology</i> , 2010, 143, 43-50.	0.8	21
96	Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: A look at the clinical and pharmacological evidence. , 2009, 123, 178-186.		75
97	Prevalence of Unresponsiveness to Aspirin and/or Clopidogrel in Patients With Stable Coronary Heart Disease. <i>American Journal of Cardiology</i> , 2009, 104, 1189-1193.	0.7	14
98	Weekâ€Long Highâ€Maintenance Dose Clopidogrel Regimen Achieves Better Platelet Aggregation Inhibition than a Standard Loading Dose before Percutaneous Coronary Intervention: Results of a Doubleâ€Blind, Randomized Clinical Trial. <i>Journal of Interventional Cardiology</i> , 2009, 22, 368-377.	0.5	7
99	Evaluation of the platelet count drop method for assessment of platelet function in comparison with â€œgold standardâ€light transmission aggregometry. <i>Thrombosis Research</i> , 2009, 124, 418-422.	0.8	17
100	Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel. <i>Thrombosis Research</i> , 2009, 124, 546-553.	0.8	16
101	Response to aspirin in healthy individuals. <i>Thrombosis and Haemostasis</i> , 2009, 102, 404-411.	1.8	66
102	Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. <i>European Heart Journal</i> , 2008, 29, 2877-2885.	1.0	133
103	Assessment of VerifyNow P2Y12 Assay Accuracy in Evaluating Clopidogrel-Induced Platelet Inhibition. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 372-378.	1.0	36
104	Comparison of different methods of measurement of aspirin resistance: using the appropriate statistic: reply. <i>European Heart Journal</i> , 2007, 29, 138-139.	1.0	1
105	A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. <i>European Heart Journal</i> , 2007, 28, 1702-1708.	1.0	465
106	Normal Response to Aspirin in Healthy Individuals: Cross-Comparison of Light Transmission Aggregometry, VerifyNowâ„¢ System, Platelet Count Drop, Thrombelastography (TEGâ„¢) and Urinary 11-dehydrothromboxane B2.. <i>Blood</i> , 2007, 110, 934-934.	0.6	0
107	Aspirin resistance: Truth or dare. , 2006, 112, 733-743.		39